Review
doi: 10.1016/j.psc.2015.05.011.
A Shared Molecular and Genetic Basis for Food and Drug Addiction: Overcoming Hypodopaminergic Trait/State by Incorporating Dopamine Agonistic Therapy in Psychiatry
Affiliations
- PMID: 26300032
- DOI: 10.1016/j.psc.2015.05.011
Item in Clipboard
Review
A Shared Molecular and Genetic Basis for Food and Drug Addiction: Overcoming Hypodopaminergic Trait/State by Incorporating Dopamine Agonistic Therapy in Psychiatry
Psychiatr Clin North Am.
2015 Sep.
Abstract
This article focuses on the shared molecular and neurogenetics of food and drug addiction tied to the understanding of reward deficiency syndrome. Reward deficiency syndrome describes a hypodopaminergic trait/state that provides a rationale for commonality in approaches for treating long-term reduced dopamine function across the reward brain regions. The identification of the role of DNA polymorphic associations with reward circuitry has resulted in new understanding of all addictive behaviors.
Keywords: Dopamine agonistic therapy; Drug addiction; Food addiction; Genetic basis; Hypodopaminergic state; Molecular basis; Psychiatry.
Copyright © 2015 Elsevier Inc. All rights reserved.
Similar articles
-
Neuro-chemical activation of brain reward meso-limbic circuitry is associated with relapse prevention and drug hunger: a hypothesis.Med Hypotheses. 2011 Apr;76(4):576-84. doi: 10.1016/j.mehy.2011.01.005. Med Hypotheses. 2011. PMID: 21306831
-
Common Neurogenetic Diagnosis and Meso-Limbic Manipulation of Hypodopaminergic Function in Reward Deficiency Syndrome (RDS): Changing the Recovery Landscape.Curr Neuropharmacol. 2017;15(1):184-194. doi: 10.2174/1570159x13666160512150918. Curr Neuropharmacol. 2017. PMID: 27174576 Free PMC article. Review.
-
Overcoming qEEG abnormalities and reward gene deficits during protracted abstinence in male psychostimulant and polydrug abusers utilizing putative dopamine D₂ agonist therapy: part 2.Postgrad Med. 2010 Nov;122(6):214-26. doi: 10.3810/pgm.2010.11.2237. Postgrad Med. 2010. PMID: 21084796 Clinical Trial.
-
Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing "deprivation-amplification relapse therapy" (DART).Postgrad Med. 2009 Nov;121(6):176-96. doi: 10.3810/pgm.2009.11.2087. Postgrad Med. 2009. PMID: 19940429 Free PMC article. Review.
-
Clinically Combating Reward Deficiency Syndrome (RDS) with Dopamine Agonist Therapy as a Paradigm Shift: Dopamine for Dinner?Mol Neurobiol. 2015 Dec;52(3):1862-1869. doi: 10.1007/s12035-015-9110-9. Epub 2015 Mar 10. Mol Neurobiol. 2015. PMID: 25750061 Free PMC article. Review.
Cited by
-
Fifty Years in the Development of a Glutaminergic-Dopaminergic Optimization Complex (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome: A Pictorial.Austin Addict Sci. 2016;1(2):1006. Epub 2016 Oct 12. Austin Addict Sci. 2016. PMID: 27840857 Free PMC article.
-
Alterations in reward network functional connectivity are associated with increased food addiction in obese individuals.Sci Rep. 2021 Feb 9;11(1):3386. doi: 10.1038/s41598-021-83116-0. Sci Rep. 2021. PMID: 33564081 Free PMC article. Clinical Trial.
-
Should We Embrace the Incorporation of Genetically Guided "Dopamine Homeostasis" in the Treatment of Reward Deficiency Syndrome (RSD) as a Frontline Therapeutic Modality?Acta Sci Neurol. 2021 Feb 2;4(2):17-24. Acta Sci Neurol. 2021. PMID: 33681869 Free PMC article.
-
Dopamine, time perception, and future time perspective.Psychopharmacology (Berl). 2018 Oct;235(10):2783-2793. doi: 10.1007/s00213-018-4971-z. Epub 2018 Jul 19. Psychopharmacology (Berl). 2018. PMID: 30027496 Free PMC article. Clinical Trial.
-
Hypothesizing Balancing Endorphinergic and Glutaminergic Systems to Treat and Prevent Relapse to Reward Deficiency Behaviors: Coupling D-Phenylalanine and N-Acetyl-L-Cysteine (NAC) as a Novel Therapeutic Modality.Clin Med Rev Case Rep. 2015;2(8):076. doi: 10.23937/2378-3656/1410076. Epub 2015 Dec 17. Clin Med Rev Case Rep. 2015. PMID: 26900600 Free PMC article. No abstract available.
